Zusammenfassung
Durchblutungsfördernde Mittel haben ihre einst führende Position bei der Behandlung peripherer arterieller Durchblutungsstörungen verloren. Seit 1992 ist das Verordnungsvolumen um 90% zurückgegangen. Damit wurde die praktische Arzneitherapie kontinuierlich an die neuen therapeutischen Möglichkeiten angepasst. Die Präparate sind zwar nach dem Arzneimittelgesetz zugelassen, haben aber nur einen fraglichen klinischen Nutzen für die Behandlung der peripheren arteriellen Verschlusskrankheit und der Claudicatio intermittens (Hiatt 2002). Wesentliche Komponenten einer optimalen Behandlung der peripheren Verschlusskrankheit ist die Senkung von Risikofaktoren durch Aufgabe des Rauchens, Senkung erhöhter Cholesterinwerte, Behandlung eines bestehenden Diabetes mellitus und Normalisierung eines erhöhten Blutdrucks (Arzneimittelkommission der deutschen Ärzteschaft 2004, Hirsch et al. 2006, Arain und Cooper 2008, Espinola-Klein 2011).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Antithrombotic Trialists’ Collaboration (2002): Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Brit Med J 324: 71–86.
Arain FA, Cooper LT (2008): Peripheral arterial disease: diagnosis and management. Mayo Clin Proc 83: 944–949
Arzneimittelkommission der deutschen Ärzteschaft (2004): Empfehlungen zur Therapie der peripheren arteriellen Verschlusskrankheit (pAVK). 3. Auflage. Arzneiverordnung in der Praxis, Band 31 Sonderheft 3. Im Internet unter: www.akdae.de/35/72_pAVK_2004_3Auflage.pdf
Barradell LB, Brogden RN (1996): Oral naftidrofuryl. A review of its pharmacology and therapeutic use in the management of peripheral occlusive arterial disease. Drugs Aging 8: 299–322.
Boccalon H, Lehert P, Mosnier M (2001): Effect of naftidrofuryl on physiological walking distance in patients with intermittent claudication. Ann Cardiol Angéiol 50: 175–182.
Conlin AE, Parnes LS (2007a): Treatment of sudden sensorineural hearing loss: I. A systematic review. Arch Otolaryngol Head Neck Surg 133: 573–581.
Conlin AE, Parnes LS (2007b): Treatment of sudden sensorineural hearing loss: II. A Meta-analysis. Arch Otolaryngol Head Neck Surg 133: 582–586.
De Backer TL, Van Der Stichele RH, Warie HH, Bogaert MG (2000): Oral vasoactive medication in intermittent claudication: utile or futile? Eur J Clin Pharmacol 56: 199–206.
De Backer TL, Vander Stichele RH, Bogaert MG (2001): Buflomedil for intermittent claudication. Cochrane Database Syst Rev (1):CD000988.
Deutsche Gesellschaft fur Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie (2010): Hörsturz (Akuter idiopathischer sensorineuraler Hörverlust). Internet: www.awmf.org/uploads/tx_szleitlinien/017-010l_S1_Hoersturz.pdf
Espinola-Klein C (2011): Periphere arterielle Verschlusskrankheit. Internist 52: 549–561.
Girolami B, Bernardi E, Prins MH, Wouter ten Cate J, Hettiarachchi R et al. (1999): Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl. Arch Intern Med 159: 337–345.
Gutacker N, Neumann A, Santosa F, Moysidis T, Kröger K (2010): Amputations in PAD patients: data from the German Federal Statistical Office. Vasc Med 15: 9–14.
Hiatt WR (2002): Pharmacological therapy for peripheral arterial disease and claudication. J Vasc Surg 36: 1283–1291.
Hiatt WR, Krantz MJ (2006): Masterclass series in peripheral arterial disease. Antiplatelet therapy for peripheral arterial disease and claudication. Vasc Med 11: 55–60.
Hirsch AT, Haskal ZJ, Hertzer NR, et al. (2006): ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary: a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients with Peripheral Arterial Disease). J Am Coll Cardiol 47: 1239–312.
Housley E (1988): Treating claudication in five words. Brit Med J 296: 1483–1484.
Gutacker N, Neumann A, Santosa F, Moysidis T, Kroger K (2010): Amputations in PAD patients: data from the German Federal Statistical Office. Vasc Med 15: 9–14.
Klemm E, Bepperling F, Burschka MA, Mösges R; Study Group (2007): Hemodilution therapy with hydroxyethyl starch solution (130/0.4) in unilateral idiopathic sudden sensorineural hearing loss: a dose-finding, double-blind, placebo-controlled, international multicenter trial with 210 patients. Otol Neurotol 28: 157–170.
McDermott MM, Liu K, Ferrucci L, Criqui MH, Greenland P, Guralnik JM, Tian L, Schneider JR, Pearce WH, Tan J, Martin GJ (2006): Physical performance in peripheral arterial disease: a slower rate of decline in patients who walk more. Ann Intern Med 144: 10–20.
Mösges R, Koberlein J, Heibges A, Erdtracht B, Klingel R, Lehmacher W; for the RHEO-ISHL Study Group (2009): Rheopheresis for idiopathic sudden hearing loss: results from a large prospective, multicenter, randomized, controlled clinical trial. Eur Arch Otorhinolaryngol 266: 943–953.
Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG; TASC II Working Group, Bell K, Caporusso J, Durand-Zaleski I, Komori K, Lammer J, Liapis C, Novo S, Razavi M, Robbs J, Schaper N, Shigematsu H, Sapoval M, White C, White J, Clement D, Creager M, Jaff M, Mohler E 3rd, Rutherford RB, Sheehan P, Sillesen H, Rosenfield K (2007): Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg Suppl 1: S1–75.
Pedersen TR, Kjekshus J, Pyörälä K, Olsson AG, Cook TJ et al. (1998): Effect of simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol 81: 333–335.
Probst R, Tschopp K, Ludin E, Kellerhals B, Podvinec M, Pfaltz CR (1992): A randomized, double-blind, placebo-controlled study of dextran/pentoxifylline medication in acute acoustic trauma and sudden hearing loss. Acta Otolaryngol 112: 435–443.
Radack K, Wyderski RJ (1990): Conservative management of intermittent claudication. Ann Intern Med 113: 135–146.
Robless P, Mikhailidis DP, Stansby GP (2008): Cilostazol for peripheral arterial disease. Cochrane Database Syst Rev. 2008 Jan 23;(1):CD003748
Schillinger M, Sabeti S, Loewe C, Dick P, Amighi J, Mlekusch W, Schlager O, Cejna M, Lammer J, Minar E (2006): Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med 354: 1879–1888.
Schreiber BE, Agrup C, Haskard DO, Luxon LM. (2010): Sudden sensorineural hearing loss. Lancet 375: 1203–1211.
Transparenzkommission (1983): Transparenzliste für das Teilgebiet periphere arterielle Durchblutungsstörungen. Bundesanzeiger Nr. 169 vom 9.9.1983.
Watson L, Ellis B, Leng GC (2008): Exercise for intermittent claudication. Cochrane Database Syst Rev. 2008 Oct 8; (4): CD000990.
Wei BP, Mubiru S, O’Leary S (2006): Steroids for idiopathic sudden sensorineural hearing loss. Cochrane Database Syst Rev. 2006 Jan 25;(1):CD003998. Review.
Weinaug P (1984): Die Spontanremission beim Hörsturz. HNO 32: 346–351
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Schwabe, U. (2011). Durchblutungsfördernde Mittel. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2011. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-21992-4_24
Download citation
DOI: https://doi.org/10.1007/978-3-642-21992-4_24
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-21991-7
Online ISBN: 978-3-642-21992-4
eBook Packages: Medicine (German Language)